CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 708 enrolled
Drug / intervention
Parenchyma-sparing resectionprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07592663
NCT07592663N/ACompleted
CompareCT.gov

Parenchyma-Sparing Resection for Pancreatic Solid Pseudopapillary Neoplasm: Oncologic Safety and Role of Lymphadenectomy in a Prospective Cohort Study

Fudan University·observational·Posted May 18, 2026·Updated May 18, 2026

In Brief

An observational study evaluating Parenchyma-sparing resection for Pancreatic Tumor, Benign and Solid Pseudopapillary Tumor of the Pancreas. Completed, enrolled 708 participants across 1 site.

Detailed Summary

Solid pseudopapillary neoplasm (SPN) of the pancreas is a low-grade malignant tumor primarily treated with surgical resection. However, the oncologic safety of parenchyma-sparing resection (PSR) and the necessity of lymphadenectomy remain debated. This prospective cohort study evaluates these aspects based on long-term outcomes.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Tumor, Benign, Solid Pseudopapillary Tumor of the Pancreas
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 18, 2026
Enrollment StartJul 1, 2008
Primary CompletionMar 1, 2026
TodayJul 2, 2026
Enrollment to primary: 17.7 yearsPosted 1 month ago

Interventions

Parenchyma-sparing resectionprocedure

PSR included enucleation (EN), duodenum-preserving pancreatic head resection (DPPHR), central pancreatectomy (CP), and spleen-preserving distal pancreatectomy (SPDP). OR included pancreatoduodenectomy (PD), distal pancreatectomy with splenectomy (DPS), and total pancreatectomy (TP).